The University of Pittsburgh-led head-to-head comparison, published in The Lancet and involving a prospective multicenter observational design with 775 enrolled participants (682 completers), demonstrates that MK6240 detects tau positivity in more than twice as many cognitively unimpaired amyloid-positive individuals (15% vs 6%) compared with the FDA-approved flortaucipir. This within-subject paired-scan approach, completed within a 45-day window alongside amyloid PET and cognitive testing, isolates tracer sensitivity differences rather than disease progression. While the source coverage emphasizes diagnostic yield, it underplays how this shift could expand anti-amyloid trial eligibility and future treatment access for millions by capturing tau at a preclinical stage when symptoms remain absent. Tau pathology's tighter correlation with cognitive decline, versus amyloid alone, means earlier staging may spare low-risk patients unnecessary therapies while accelerating disease-modifying interventions. An observational study of this scale lacks randomization but gains rigor from its paired design; no major conflicts of interest were disclosed beyond institutional affiliations. Complementary evidence from a 2023 JAMA Neurology analysis of MK6240 kinetics (n=301) and a 2024 Alzheimer's & Dementia meta-analysis of tau PET tracers reinforces that second-generation ligands like MK6240 bind earlier Braak stages with higher affinity, a pattern missed in incremental biomarker reports. Together these data suggest a practical advance capable of compressing diagnostic timelines and widening prevention windows beyond current standards.